[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Duchenne Muscular Dystrophy Global Clinical Trials Review, H1, 2019

May 2019 | 197 pages | ID: D21C71E4646EN
GlobalData

US$ 2,500.00

Email Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Duchenne Muscular Dystrophy Global Clinical Trials Review, H1, 2019

SUMMARY

GlobalData's clinical trial report, “Duchenne Muscular Dystrophy Global Clinical Trials Review, H1, 2019' provides an overview of Duchenne Muscular Dystrophy clinical trials scenario. This report provides top line data relating to the clinical trials on Duchenne Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

REASONS TO BUY
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Countries Contributing to Clinical Trials in Middle East and Africa
Top Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Duchenne Muscular Dystrophy Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Duchenne Muscular Dystrophy
May 02, 2019: Catabasis Pharmaceuticals to present data from the MoveDMD trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 71st Annual Meeting
Apr 20, 2019: Catabasis opens new UK sites in Edasalonexent trial
Apr 16, 2019: Wave Life Sciences announces Suvodirsen phase 1 safety and tolerability data and phase 2/3 clinical trial design
Apr 15, 2019: Santhera to Present Long-term efficacy results with Idebenone in DMD at the 2019 MDA Clinical and Scientific Conference
Apr 12, 2019: Wave Life Sciences to host investor conference call to discuss Suvodirsen DMD clinical data being presented at MDA Clinical and scientific conference
Apr 04, 2019: Antisense Therapeutics provides update on its phase II clinical trial in Duchenne Muscular Dystrophy
Apr 01, 2019: Catabasis Pharmaceuticals to present at upcoming Neuromuscular Translational Research Conference and MDA Clinical and Scientific Conference
Mar 28, 2019: Sarepta Therapeutics announces positive expression results from the Casimersen (SRP-4045) arm of the ESSENCE study
Mar 25, 2019: Wave Life Sciences to present Suvodirsen phase 1 safety and tolerability data and phase 2/3 clinical trial design at the muscular dystrophy association clinical and scientific conference
Mar 25, 2019: Sarepta Therapeutics to provide update on Duchenne Muscular Dystrophy gene therapy program
Feb 26, 2019: Santhera reports positive data from idebenone trial in DMD patients
Feb 19, 2019: Catabasis Pharmaceuticals presents data supporting Edasalonexent as a potential foundational treatment for Duchenne Muscular Dystrophy
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Disclaimer
Source

LIST OF TABLES

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region, 2019*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries, 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries, 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Countries, 2019*
Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2019*
Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2019*
Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase, 2019*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase 2019*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*

LIST OF FIGURES

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region (%), 2019*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries (%), 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2019*
Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2019*
Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2019*
Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase (%), 2019*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase, 2019*
Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
GlobalData Methodology

COMPANIES MENTIONED

PTC Therapeutics Inc
Sarepta Therapeutics Inc
BioMarin Pharmaceutical Inc
GlaxoSmithKline Plc
Summit Therapeutics Plc
ReveraGen BioPharma Inc
Catabasis Pharmaceuticals Inc
Akashi Therapeutics Inc
Santhera Pharmaceuticals Holding AG


More Publications